Literature DB >> 639432

Doxepin kinetics.

V E Ziegler, J T Biggs, L T Wylie, S H Rosen, D J Hawf, W H Coryell.   

Abstract

The kinetics of doxepin (DOX) hydrochloride were studied in 7 volunteers after the oral administration of 75 mg. Peak plasma concentrations of DOX ranged from 8.8 to 45.8 ng/ml and were reached within 4 hr. The disappearance of DOX was biphasic and followed first-order kinetics. The mean DOX half life (t1/2) was 16.8 hr and in individuals ranged from 8.2 to 24.5 hr. The mean apparent volume of distribution was 20.2 L/kg and ranged from 9.1 to 33.3 L/kg. The estimated first-pass metabolism of DOX ranged from 55% to 87% of the oral dose assuming complete absorption. Significant quantities of the metabolite desmethyldoxepin (DMD) were produced. Peak levels of DMD ranged from 4.8 to 14.5 ng/ml and were reached between 2 and 10 hr after administration. The mean t1/2 of DMD was 51.3 hr and in individuals ranged from 33.2 to 80.7 hr. There was no correlation between the DOX and DMD t1/2s. The amount of DMD produced correlated with the plasma concentration of DOX and appears to explain the correlation between the steady-state concentrations of DOX and DMD in patients given DOX.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639432     DOI: 10.1002/cpt1978235573

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Formation of active metabolites of psychotropic drugs. An updated review of their significance.

Authors:  S Caccia; S Garattini
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  The influence of cimetidine versus ranitidine on doxepin pharmacokinetics.

Authors:  D L Sutherland; A J Remillard; K R Haight; M A Brown; L Old
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

4.  Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.

Authors:  D M Cocchetto; W A Wargin; J W Crow
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

5.  Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients.

Authors:  P D Hrdina; D Bakish; S Swenson; Y D Lapierre
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

Review 6.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

Review 7.  Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison.

Authors:  A el-Yazigi; K Chaleby
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Amitriptyline pharmacokinetics. A crossover study with single doses of amitriptyline and nortriptyline.

Authors:  J E Burch; R P Hullin
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Predictions of in vivo plasma concentrations from in vitro release kinetics: application to doxepin parenteral (i.m.) suspensions in lipophilic vehicles in dogs.

Authors:  C Gido; P Langguth; E Mutschler
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

10.  First-pass metabolism of nomifensine in dogs.

Authors:  R Lindberg; R Sellman; E Iisalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.